Svetlana Selivanova is radiochemist and subject-matter expert in radiopharmaceutical sciences. She earned her BSc in chemistry (with physics and mathematics; Prof. Natalia Essina) and MSc in chemistry (Prof. Aslan Tsivadze) from Peoples’ Friendship University of Russia, and PhD in radiopharmaceutical chemistry and radiobiology from Université de Sherbrooke (Prof. Johan van Lier, Prof. Svetlana Kudrevich). After several years of postdoctoral research at Clinical Research Centre Étienne-Le-Bel (Prof. Francois Benard) and at ETH Zurich (Prof. August Schubiger, Prof. Simon Ametamey), she was promoted as a group leader and deputy head at the Centre for Radiopharmaceutical Sciences at ETH Zurich. In 2012, she was invited by CRCHU de Sherbrooke to lead the radiopharmaceutical development of commercial-scale production of Tc-99m medical isotope by cyclotron. She was recruited by CHU de Quebec – Université Laval in 2017 to set up new cyclotron and radiopharmaceutical facility. Internationally, she is a member of several professional societies, is active as expert for the European Commission Research Executive Agency, and serves as Director and Treasurer on the SNMMI Radiopharmaceutical Sciences Council Board of Directors.

Dr. Selivanova has extensive experience in cyclotron production of medical isotopes, nuclear and radiochemistry, radiopharmacology, and development of radiopharmaceuticals at all stages from early R&D to first-in-human clinical trials and cGMP. Her research interests are multidisciplinary and encompass, at large, development and application of small-molecule radiolabelled compounds for molecular imaging, therapy, and in support of drug development. Radiolabelled compounds open fascinating opportunities for fundamental science and for clinical practice and have a range of applications in medical diagnostics, drug discovery, and assessment of therapeutic interventions. These molecules deliver information about body metabolism, receptors function or drug pharmacology and, thereby, enable in vivo study of normal and pathological biochemical processes and physiology on molecular as well as systemic level. As a member of the Oncology axis, Svetlana Selivanova is involved in several projects focused on innovative cancer theranostics and translational research.

Hôpital de l'Enfant-Jésus
1401, 18e rue
Pavillon Notre Dame
H-308
Québec, Qc
Canada G1L 1Z4
+1 418-525-4444, extension 64370
svetlana.selivanova@chude... svetlana.selivanova@crchu...

Latest news

Data not available

19 entries « ‹ 1 of 2 › »

Brugarolas P, Comstock J, Dick DW, Ellmer T, Engle JW, Lapi SE, Liang SH, Parent EE, Kishore Pillarsetty NV, Selivanova S, Sun X, Vavere A, Scott PJH

Fifty Years of Radiopharmaceuticals.

Journal Article

J Nucl Med Technol, 48 (Suppl 1), 2020, ISSN: 0091-4916.

Abstract | Links:

Andersson JD, Thomas B, Selivanova SV, Berthelette E, Wilson JS, McEwan AJB, Gagnon K

Robust high-yield ~1 TBq production of cyclotron based sodium [Tc]pertechnetate.

Journal Article

Nucl Med Biol, 60 , 2018.

Abstract | Links:

Mcquarrie SA, Gagnon K, Andersson J, Wilson J, Schirrmacher E, Thomas B, Lecomte R, Selivanova S, Senta H, Guérin B, Turcotte E, Zyuzin A, McEwan AJB

Accelerator-based alternatives to non-HEU production of 99Mo/99mTc

Book Chapter

Cyclotron based production of technetium-99m (Annex II, Supporting Material : Final report of the coordinated project on Accelerator-based Alternatives to Non-HEU Production of Mo-99 /Tc-99m), pp. 31-51, Vienna, IAEA, 2017, ISBN: 9789201029164.

Selivanova SV, Lavallee E, Senta H, Caouette L, McEwan AJB, Guerin B, Lecomte R, Turcotte E

Clinical Trial with Sodium Tc-Pertechnetate Produced by a Medium-Energy Cyclotron: Biodistribution and Safety Assessment in Patients with Abnormal Thyroid Function.

Journal Article

J Nucl Med, 58 (5), 2017.

Abstract | Links:

Selivanova SV, Lavallee E, Senta H, Caouette L, Sader JA, van Lier EJ, Zyuzin A, van Lier JE, Guerin B, Turcotte E, Lecomte R

Radioisotopic Purity of Sodium Pertechnetate 99mTc Produced with a Medium-Energy Cyclotron: Implications for Internal Radiation Dose, Image Quality, and Release Specifications.

Journal Article

J Nucl Med, 56 (10), 2015.

Abstract | Links:

Selivanova SV, Toscano A, Abate C, Berardi F, Muller A, Kramer SD, Schibli R, Ametamey SM

Synthesis and pharmacological evaluation of ¹¹C-labeled piperazine derivative as a PET probe for sigma-2 receptor imaging.

Journal Article

Nucl Med Biol, 42 (4), 2015.

Abstract | Links:

Chiotellis A, Selivanova SV, Schweizer B, Schibli R, Ametamey SM

Studies towards terminal (fluoroalkyl)silanes. Investigation of diethylaminosulfur trifluoride (DAST) in exchange reactions with terminal (hydroxyalkyl)silanes

Journal Article

J Fluor Chem, 160 , 2014.

| Links:

Leopoldo M, Selivanova SV, Muller A, Lacivita E, Schetz JA, Ametamey SM

In vitro and in vivo evaluation of N-{2-[4-(3-Cyanopyridin-2-yl)piperazin-1-yl]ethyl}-3-[(11) C]methoxybenz-amide, a positron emission tomography (PET) radioligand for dopamine D4 receptors, in rodents.

Journal Article

Chem Biodivers, 11 (9), 2014.

Abstract | Links:

Muller A, Kramer SD, Meletta R, Beck K, Selivanova SV, Rancic Z, Kaufmann PA, Vos B, Meding J, Stellfeld T, Heinrich TK, Bauser M, Hutter J, Dinkelborg LM, Schibli R, Ametamey SM

Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.

Journal Article

Nucl Med Biol, 41 (7), 2014.

Abstract | Links:

Chiotellis A, Mu L, Muller A, Selivanova SV, Keller C, Schibli R, Kramer SD, Ametamey SM

Synthesis and biological evaluation of ¹⁸F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging.

Journal Article

Eur J Med Chem, 70 , 2013.

Abstract | Links:

19 entries « ‹ 1 of 2 › »
Signaler des ajouts ou des modifications